Myeloma Bone Disease
Humana Press Inc. (Verlag)
978-1-61779-688-3 (ISBN)
Multiple myeloma is the second most common hematologic malignancy and c- rently affects approximately 50,000 people in the United States. Each year about 20,000 people are diagnosed with myeloma. Although new treatments have been developed, which signi?cantly prolong the survival of patients, myeloma bone d- ease still remains a major cause of severe morbidity and increased mortality in patients with myeloma. Myeloma bone disease is characterized by "punched out" lytic lesions caused by increased osteoclastic bone destruction accompanied by suppressed or even absent osteoblast activity. Advances in our understanding of both the pathophysiology of myeloma bone disease and the development of novel agents that target speci?c pathways involved in both the increased osteoclast f- mation and the suppressed osteoblast activity in myeloma provide new hope for these patients. The treatment of myeloma bone disease was revolutionized by cl- ical trials that demonstrated the signi?cant bene?t of intravenous bisphosphonate therapy in patients with myeloma bone disease. With the identi?cation of many of the cytokines and chemokines involved in myeloma bone disease, novel th- apies such as denosumab that blocks RANKL activity, anti-DKK1, which targets the inhibition of osteoblast activity by blocking Wnt signaling inhibition, and the potential anabolic effects of agents such as bortezomib and activin have greatly improved our potential to block the progression or reverse myeloma bone disease.
Clinical Presentation of Myeloma Bone Disease.- Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias.- Biochemical Markers of Bone Remodeling in Multiple Myeloma.- Radiation Therapy in Multiple Myeloma.- Surgical Management of Bone Disease.- Bisphosphonates in the Treatment of Myeloma Bone Disease.- Osteonecrosis of the Jaw.- Murine Models of Myeloma Bone Disease: The Importance of Choice.- RANK Ligand Is a Therapeutic Target in Multiple Myeloma.- Osteoclast Activation in Multiple Myeloma.- Potential Role of IMiDs and Other Agents as Therapy for Myeloma Bone Disease.- Proteasome Inhibitors and the Wnt Signaling Pathway in Myeloma Bone Disease.- Mechanisms Involved in Osteoblast Suppression in Multiple Myeloma.
| Reihe/Serie | Current Clinical Oncology |
|---|---|
| Zusatzinfo | 43 Illustrations, color; 32 Illustrations, black and white; X, 252 p. 75 illus., 43 illus. in color. |
| Verlagsort | Totowa, NJ |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Radiologie / Bildgebende Verfahren | |
| Schlagworte | Bisphosphonates • Bone Disease • Bortezomib • Denosumab • kyphoplasty • multiple myeloma • Osteoblasts • Osteoclasts • Osteonecrosis of the jaw • radiation therapy • vertebroplasty |
| ISBN-10 | 1-61779-688-3 / 1617796883 |
| ISBN-13 | 978-1-61779-688-3 / 9781617796883 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
